Hidradenitis Suppurativa - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Hidradenitis Suppurativa - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Hidradenitis Suppurativa pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Hidradenitis Suppurativa: Overview
Hidradenitis suppurativa (HS) is a chronic or relapsing inflammatory skin disease affecting hair follicles in intertriginous areas, including the axillary, inframammary, inguinal, genital, buttocks, and perianal/perineal areas. With a prevalence of 1 to 4 percent, HS is not an uncommon disease. It affects three times as many women as men, and one-third of HS patients report a positive family history. Other predisposing factors include smoking and obesity. The clinical features of HS are recurrent, painful nodules and abscesses, fistulas, sinus tracts (tunnels), and scarring. Patients with HS have significantly impaired quality of life due to both physical and psychological discomfort associated with the disease (e.g., pain, suppuration, social isolation, and work disability). Several conditions, including inflammatory bowel disease, metabolic syndrome, arthritis, and depression, have been reported to co-occur with HS.
'Hidradenitis Suppurativa - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hidradenitis Suppurativa pipeline landscape is provided which includes the disease overview and Hidradenitis Suppurativa treatment guidelines. The assessment part of the report embraces, in depth Hidradenitis Suppurativa commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hidradenitis Suppurativa collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Hidradenitis Suppurativa report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Hidradenitis Suppurativa Emerging Drugs
Further product details are provided in the report……..
Hidradenitis Suppurativa: Therapeutic Assessment
This segment of the report provides insights about the different Hidradenitis Suppurativa drugs segregated based on following parameters that define the scope of the report, such as:
Hidradenitis Suppurativa: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hidradenitis Suppurativa therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hidradenitis Suppurativa drugs.
Hidradenitis Suppurativa Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Hidradenitis Suppurativa - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Hidradenitis Suppurativa pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Hidradenitis Suppurativa: Overview
Hidradenitis suppurativa (HS) is a chronic or relapsing inflammatory skin disease affecting hair follicles in intertriginous areas, including the axillary, inframammary, inguinal, genital, buttocks, and perianal/perineal areas. With a prevalence of 1 to 4 percent, HS is not an uncommon disease. It affects three times as many women as men, and one-third of HS patients report a positive family history. Other predisposing factors include smoking and obesity. The clinical features of HS are recurrent, painful nodules and abscesses, fistulas, sinus tracts (tunnels), and scarring. Patients with HS have significantly impaired quality of life due to both physical and psychological discomfort associated with the disease (e.g., pain, suppuration, social isolation, and work disability). Several conditions, including inflammatory bowel disease, metabolic syndrome, arthritis, and depression, have been reported to co-occur with HS.
'Hidradenitis Suppurativa - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hidradenitis Suppurativa pipeline landscape is provided which includes the disease overview and Hidradenitis Suppurativa treatment guidelines. The assessment part of the report embraces, in depth Hidradenitis Suppurativa commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hidradenitis Suppurativa collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Hidradenitis Suppurativa R&D. The therapies under development are focused on novel approaches to treat/improve Hidradenitis Suppurativa.
This segment of the Hidradenitis Suppurativa report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Hidradenitis Suppurativa Emerging Drugs
- Secukinumab: Novartis
- IFX-1: InflaRx
Further product details are provided in the report……..
Hidradenitis Suppurativa: Therapeutic Assessment
This segment of the report provides insights about the different Hidradenitis Suppurativa drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Hidradenitis Suppurativa
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Hidradenitis Suppurativa: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hidradenitis Suppurativa therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hidradenitis Suppurativa drugs.
Hidradenitis Suppurativa Report Insights
- Hidradenitis Suppurativa Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Hidradenitis Suppurativa drugs?
- How many Hidradenitis Suppurativa drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hidradenitis Suppurativa?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hidradenitis Suppurativa therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Hidradenitis Suppurativa and their status?
- What are the key designations that have been granted to the emerging drugs?
- InflaRx
- Novartis
- UCB
- ChemoCentryx
- Eli Lilly and Company
- Janssen Biotech
- AbbVie
- Pfizer
- Amgen
- Incyte Corporation
- CSL Behring
- IFX-1
- Secukinumab
- Bimekizumab
- Avacopan
- LY3041658
- Bermekimab
- Guselkumab
- Risankizumab
- PF 6650833
- Apremilast
- INCB54707
- CSL324
Introduction
Executive Summary
Hidradenitis Suppurativa: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Secukinumab: Novartis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Avacopan: ChemoCentryx
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CSL324: CSL Behring
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Hidradenitis Suppurativa Key Companies
Hidradenitis Suppurativa Key Products
Hidradenitis Suppurativa- Unmet Needs
Hidradenitis Suppurativa- Market Drivers and Barriers
Hidradenitis Suppurativa- Future Perspectives and Conclusion
Hidradenitis Suppurativa Analyst Views
Hidradenitis Suppurativa Key Companies
Appendix
Executive Summary
Hidradenitis Suppurativa: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Secukinumab: Novartis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Avacopan: ChemoCentryx
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CSL324: CSL Behring
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Hidradenitis Suppurativa Key Companies
Hidradenitis Suppurativa Key Products
Hidradenitis Suppurativa- Unmet Needs
Hidradenitis Suppurativa- Market Drivers and Barriers
Hidradenitis Suppurativa- Future Perspectives and Conclusion
Hidradenitis Suppurativa Analyst Views
Hidradenitis Suppurativa Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Hidradenitis Suppurativa
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Hidradenitis Suppurativa
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Hidradenitis Suppurativa
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Hidradenitis Suppurativa
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products